查詢結果分析
來源資料
相關文獻
- Use of Botulinum Toxin A in the Treatment of Hemifacial Spasm and Blepharospasm
- 良性自發性眼瞼痙攣症(Benign Essential Blepharospasm)的臨床症狀與治療原則
- 原發性眼瞼痙攣之手術治療
- 眼瞼痙攣症之針灸治療
- Clinical Experience in the Treatment of Hemifacial Spasm with Low Dose Botulinum Toxin A
- Quantitative Assessment of Efficacy of Dysport (Botulinum Toxin Type A) in the Treatment of Idiopathic Blepharospasm and Hemifacial Spasm
- 顱顏肌肉的不自主運動:雙側眼瞼痙攣與半邊顏面痙攣
- Comparison of the Therapeutic Effects of Urethral Injections of 50 and 100 Units of Botulinum A Toxin for Voiding Dysfunction
- 肉毒桿菌素在眼科醫療領域的應用
頁籤選單縮合
題名 | Use of Botulinum Toxin A in the Treatment of Hemifacial Spasm and Blepharospasm=肉毒桿菌素A用於治療半側顏面痙攣及眼瞼痙攣 |
---|---|
作者 | 張烈賓; 蔡清標; 廖光淦; 高克培; 袁志綸; 顏得楨; 林恭平; Chang, Lei-bin; Tsai, Ching-piao; Liao, Kwong-kum; Kao, Ko-pei; Yuan, Chih-lun; Yen, Der-jen; Lin, Kong-pin; |
期刊 | 中華醫學雜誌 |
出版日期 | 19990100 |
卷期 | 62:1 1999.01[民88.01] |
頁次 | 頁1-5 |
分類號 | 415.831 |
語文 | eng |
關鍵詞 | 眼瞼痙攣; 肉毒桿菌素A; 半側顏面痙攣; Blepharospasm; Botulinum toxin A; Hemifacial spasm; |
中文摘要 | 背景 半側顏面痙攣及眼瞼痙攣,是一種不自主的、局部性的半側顏面或眼瞼的 肌肉痙攣或抽搐,患者的生活常受嚴重影響。1990年美國食品與藥物管理局核准了用肉毒 桿菌素A治療此類患者。本文報告台灣80例接受此藥治療的個案。 方法 80例個案中,半側顏面痙攣者有58例,眼瞼痙攣者有22例。將肉毒桿菌素A 皮下局部注射於患部肌肉,之後每隔2週追蹤檢查,將其進展予以4級分類,同時觀察是否 有副作用發生,並記錄統計之。 結果 結果顯示,半側顏面痙攣及眼瞼痙攣的個案中,分別有86.2%和81.8%有良好的 進步;6.8%和9.0%有中等程度的進步。副作用的發生率,以暫時性的輕度顏面無力(5%)、 眼瞼下垂(3.8%)、眼瞼腫脹或瘀血(3.8%)、噁心嘔吐(2.5%)和暫時性的重度顏面無力(1.3%)為 主。 結論 肉毒桿菌素A在治療半側顏面痙攣及眼瞼痙攣方面,療效良好且副作用少,是 一項既有效又安全的治療方法。 |
英文摘要 | Background. Hemifacial spasm and blepharospasm are both dystonic disorders. They may seriously affect individuals' lifestyle and social activities. In 1990, the Food and Drug Administration of the USA approved botulinum toxin A as a therapeutic agent in the treatment of hemifacial spasm and blepharospasm. We present a therapeutic review of botulinum toxin A in 80 patients in Taiwan. Methods. Fifty-eight patients with hemifacial spasm and 22 with blepharospasm. Botulinum toxin A was prepared and injected into the facial and eyelid muscles. Patients were monitored every two weeks and classified into four groups (excellent, moderate, mild and no improvement) according to the clinical improvement scale. Complications were also recorded. Results. A total of 86.2% of hemifacial spasm patients and 81.8% of blepharospasm patients had excellent improvement on the spasm intensity scale, while 6.8% of hemifacial spasm and 9.0% of blepharospasm patients had moderate improvement. The complication rate was low and included transient mild facial weakness (5%), ptosis (3.8%), eyelid swelling and/or ecchymosis (3.8%), nausea/vomiting (2.5%) and transient severe facial weakness (1.3%) Conclusion. Botulinum toxin A is an excellent therapeutic agent to improve spasm intensity and has a low complication rate. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。